Treatment Options for Triple-Negative Breast Cancer Prof. Peter Schmid

Integrating Antibody-Drug Conjugates into MGMT of HR+ and Triple-Negative Metastatic Breast CancerПодробнее

Other Targets for ADC Therapy in mBC — Professor Peter Schmid, FRCP, MD, PhDПодробнее

Video Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Fu...Подробнее

New and emerging agents in HER2-negative metastatic breast cancer: Implications for practiceПодробнее

ClarifyingComplexities of ExpandingTreatmentOptionsFor AdvancedAndEarly-Stage HR+/HER2- BreastCancerПодробнее

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment ArsenalПодробнее

Current gold standard for TNBC and Future direction | Peter SchmidПодробнее

Prof. Peter Schmid | Presentation | 2nd Breast Cancer Preceptorship Program | BSBCSПодробнее

The role of immunotherapy in advanced TNBC Prof. Peter SchmidПодробнее

ASCO DIRECT HIGHLIGHT 2020 Riyadh [Day 2]Подробнее

eCME on "How shall we Treat Triple-Negative Breast Cancer (TNBC)"Подробнее

Pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembr...Подробнее

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...Подробнее

Challenges in the treatment of mTNBCПодробнее

Comment on new treatment options for breast cancerПодробнее

Personalised treatment of breast cancer: is there a realistic hope?Подробнее